4tq9 › Citations

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD
Mol Cancer Res 13 1325-35 (2015)
Related entries: 4ql3, 4tqa, 4wa7

Cited: 323 times
EuropePMC logo PMID: 26037647

Articles - 4tq9 mentioned but not cited (11)

  1. Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange. Guillard S, Kolasinska-Zwierz P, Debreczeni J, Breed J, Zhang J, Bery N, Marwood R, Tart J, Overman R, Stocki P, Mistry B, Phillips C, Rabbitts T, Jackson R, Minter R. Nat Commun 8 16111 (2017)
  2. KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. Bery N, Legg S, Debreczeni J, Breed J, Embrey K, Stubbs C, Kolasinska-Zwierz P, Barrett N, Marwood R, Watson J, Tart J, Overman R, Miller A, Phillips C, Minter R, Rabbitts TH. Nat Commun 10 2607 (2019)
  3. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function. Cao S, Chung S, Kim S, Li Z, Manor D, Buck M. J Biol Chem 294 7068-7084 (2019)
  4. A structural model of a Ras-Raf signalosome. Mysore VP, Zhou ZW, Ambrogio C, Li L, Kapp JN, Lu C, Wang Q, Tucker MR, Okoro JJ, Nagy-Davidescu G, Bai X, Plückthun A, Jänne PA, Westover KD, Shan Y, Shaw DE. Nat Struct Mol Biol 28 847-857 (2021)
  5. Exceptionally high-affinity Ras binders that remodel its effector domain. McGee JH, Shim SY, Lee SJ, Swanson PK, Jiang SY, Durney MA, Verdine GL. J Biol Chem 293 3265-3280 (2018)
  6. Organization of Farnesylated, Carboxymethylated KRAS4B on Membranes. Barklis E, Stephen AG, Staubus AO, Barklis RL, Alfadhli A. J Mol Biol 431 3706-3717 (2019)
  7. Biochemical characterization of the interaction between KRAS and Argonaute 2. Waninger JJ, Beyett TS, Gadkari VV, Siebenaler RF, Kenum C, Shankar S, Ruotolo BT, Chinnaiyan AM, Tesmer JJG. Biochem Biophys Rep 29 101191 (2022)
  8. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. Zhang Y, Larraufie MH, Musavi L, Akkiraju H, Brown LM, Stockwell BR. Biochemistry 57 1380-1389 (2018)
  9. 2-Pyridin-4-yl-methylene-beta-boswellic Acid-A Potential Candidate for Targeting O6-Methylguanine-DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D-Microsatellite Stable, G12V-Microsatellite Instable Mutant Colon Cancer. Qayum A, Singh J, Kumar A, Shah SM, Srivastava S, Kushwaha M, Magotra A, Nandi U, Malik R, Shah BA, Singh SK. ACS Pharmacol Transl Sci 5 306-320 (2022)
  10. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. Poorebrahim M, Abazari MF, Moradi L, Shahbazi B, Mahmoudi R, Kalhor H, Askari H, Teimoori-Toolabi L. PLoS Comput Biol 18 e1009962 (2022)
  11. Wavelet coherence phase analysis decodes the universal switching mechanism of Ras GTPase superfamily. Motiwala Z, Sandholu AS, Sengupta D, Kulkarni K. iScience 26 107031 (2023)


Reviews citing this publication (113)

  1. RAS Proteins and Their Regulators in Human Disease. Simanshu DK, Nissley DV, McCormick F. Cell 170 17-33 (2017)
  2. RAS isoforms and mutations in cancer at a glance. Hobbs GA, Der CJ, Rossman KL. J Cell Sci 129 1287-1292 (2016)
  3. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Waters AM, Der CJ. Cold Spring Harb Perspect Med 8 a031435 (2018)
  4. The Frequency of Ras Mutations in Cancer. Prior IA, Hood FE, Hartley JL. Cancer Res 80 2969-2974 (2020)
  5. RAS-targeted therapies: is the undruggable drugged? Moore AR, Rosenberg SC, McCormick F, Malek S. Nat Rev Drug Discov 19 533-552 (2020)
  6. Genetics and biology of pancreatic ductal adenocarcinoma. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genes Dev 30 355-385 (2016)
  7. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Ostrem JM, Shokat KM. Nat Rev Drug Discov 15 771-785 (2016)
  8. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Buscail L, Bournet B, Cordelier P. Nat Rev Gastroenterol Hepatol 17 153-168 (2020)
  9. KRAS Alleles: The Devil Is in the Detail. Haigis KM. Trends Cancer 3 686-697 (2017)
  10. Therapeutic strategies to target RAS-mutant cancers. Ryan MB, Corcoran RB. Nat Rev Clin Oncol 15 709-720 (2018)
  11. A model for RAS mutation patterns in cancers: finding the sweet spot. Li S, Balmain A, Counter CM. Nat Rev Cancer 18 767-777 (2018)
  12. KRAS mutation: from undruggable to druggable in cancer. Huang L, Guo Z, Wang F, Fu L. Signal Transduct Target Ther 6 386 (2021)
  13. KRAS-related proteins in pancreatic cancer. Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. Pharmacol Ther 168 29-42 (2016)
  14. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Kim D, Xue JY, Lito P. Cell 183 850-859 (2020)
  15. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Muñoz-Maldonado C, Zimmer Y, Medová M. Front Oncol 9 1088 (2019)
  16. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. Cancer Treat Rev 84 101974 (2020)
  17. The current understanding of KRAS protein structure and dynamics. Pantsar T. Comput Struct Biotechnol J 18 189-198 (2020)
  18. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Timar J, Kashofer K. Cancer Metastasis Rev 39 1029-1038 (2020)
  19. Pharmacological targeting of RAS: Recent success with direct inhibitors. O'Bryan JP. Pharmacol Res 139 503-511 (2019)
  20. Precision oncology in metastatic colorectal cancer - from biology to medicine. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Nat Rev Clin Oncol 18 506-525 (2021)
  21. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Zhu G, Pei L, Xia H, Tang Q, Bi F. Mol Cancer 20 143 (2021)
  22. The current state of the art and future trends in RAS-targeted cancer therapies. Punekar SR, Velcheti V, Neel BG, Wong KK. Nat Rev Clin Oncol 19 637-655 (2022)
  23. RAS variant signalling. Mo SP, Coulson JM, Prior IA. Biochem Soc Trans 46 1325-1332 (2018)
  24. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Stalnecker CA, Der CJ. Sci Signal 13 eaay6013 (2020)
  25. Mechanisms of Resistance to KRASG12C Inhibitors. Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Cancers (Basel) 13 E151 (2021)
  26. Direct inhibition of RAS: Quest for the Holy Grail? Spencer-Smith R, O'Bryan JP. Semin Cancer Biol 54 138-148 (2019)
  27. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down. Hobbs GA, Wittinghofer A, Der CJ. Cancer Cell 29 251-253 (2016)
  28. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Kwan AK, Piazza GA, Keeton AB, Leite CA. J Exp Clin Cancer Res 41 27 (2022)
  29. The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding. Banerjee A, Jang H, Nussinov R, Gaponenko V. Curr Opin Struct Biol 36 10-17 (2016)
  30. Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C. Cancers (Basel) 11 E1133 (2019)
  31. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Molina-Arcas M, Samani A, Downward J. Genes (Basel) 12 899 (2021)
  32. KRasG12C inhibitors in clinical trials: a short historical perspective. Goebel L, Müller MP, Goody RS, Rauh D. RSC Med Chem 11 760-770 (2020)
  33. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Tang D, Kroemer G, Kang R. Mol Cancer 20 128 (2021)
  34. PROTACs to address the challenges facing small molecule inhibitors. Martín-Acosta P, Xiao X. Eur J Med Chem 210 112993 (2021)
  35. Strategies to tackle RAS-mutated metastatic colorectal cancer. Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. ESMO Open 6 100156 (2021)
  36. Non-Coding RNAs in Lung Tumor Initiation and Progression. Santos RM, Moreno C, Zhang WC. Int J Mol Sci 21 E2774 (2020)
  37. Targeting mutations in cancer. Waarts MR, Stonestrom AJ, Park YC, Levine RL. J Clin Invest 132 e154943 (2022)
  38. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Cancer Metastasis Rev 40 819-835 (2021)
  39. The effects of mutant Ras proteins on the cell signalome. Takács T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. Cancer Metastasis Rev 39 1051-1065 (2020)
  40. The renewed battle against RAS-mutant cancers. Zhang F, Cheong JK. Cell Mol Life Sci 73 1845-1858 (2016)
  41. Targeting KRAS mutant lung cancer: light at the end of the tunnel. Drosten M, Barbacid M. Mol Oncol 16 1057-1071 (2022)
  42. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Désage AL, Léonce C, Swalduz A, Ortiz-Cuaran S. Front Oncol 12 796832 (2022)
  43. Drugging KRAS: current perspectives and state-of-art review. Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. J Hematol Oncol 15 152 (2022)
  44. Inhibition of Nonfunctional Ras. Nussinov R, Jang H, Gursoy A, Keskin O, Gaponenko V. Cell Chem Biol 28 121-133 (2021)
  45. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Nollmann FI, Ruess DA. Biomedicines 8 E281 (2020)
  46. Targeting the undruggable oncogenic KRAS: the dawn of hope. Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. JCI Insight 7 e153688 (2022)
  47. A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Heppner DE, Eck MJ. Protein Sci 30 1535-1553 (2021)
  48. Inhibition of RAS: proven and potential vulnerabilities. Zuberi M, Khan I, O'Bryan JP. Biochem Soc Trans 48 1831-1841 (2020)
  49. Mechanism of activation and the rewired network: New drug design concepts. Nussinov R, Zhang M, Maloney R, Tsai CJ, Yavuz BR, Tuncbag N, Jang H. Med Res Rev 42 770-799 (2022)
  50. Precision medicine for metastatic colorectal cancer in clinical practice. Riedesser JE, Ebert MP, Betge J. Ther Adv Med Oncol 14 17588359211072703 (2022)
  51. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Erickson KE, Rukhlenko OS, Posner RG, Hlavacek WS, Kholodenko BN. Semin Cancer Biol 54 162-173 (2019)
  52. Pumping the brakes on RAS - negative regulators and death effectors of RAS. Harrell Stewart DR, Clark GJ. J Cell Sci 133 jcs238865 (2020)
  53. Rationale for RAS mutation-tailored therapies. Montalvo SK, Li L, Westover KD. Future Oncol 13 263-271 (2017)
  54. Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology. László L, Kurilla A, Takács T, Kudlik G, Koprivanacz K, Buday L, Vas V. Cells 10 667 (2021)
  55. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. Nussinov R, Zhang M, Maloney R, Liu Y, Tsai CJ, Jang H. J Mol Biol 434 167569 (2022)
  56. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Bannoura SF, Khan HY, Azmi AS. Front Oncol 12 1013902 (2022)
  57. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Ann Gastroenterol Surg 5 457-466 (2021)
  58. T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy. Duan Z, Ho M. Mol Cancer Ther 20 1533-1541 (2021)
  59. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Blaquier JB, Cardona AF, Recondo G. Front Oncol 11 787585 (2021)
  60. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Gillson J, Abd El-Aziz YS, Leck LYW, Jansson PJ, Pavlakis N, Samra JS, Mittal A, Sahni S. Cancers (Basel) 14 3528 (2022)
  61. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. Mattox TE, Chen X, Maxuitenko YY, Keeton AB, Piazza GA. Int J Mol Sci 21 E141 (2019)
  62. Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy. Chen FY, Li X, Zhu HP, Huang W. Front Pharmacol 11 280 (2020)
  63. Emerging RAS-directed therapies for cancer. Conroy M, Cowzer D, Kolch W, Duffy AG. Cancer Drug Resist 4 543-558 (2021)
  64. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift. Nyíri K, Koppány G, Vértessy BG. Cancer Metastasis Rev 39 1091-1105 (2020)
  65. Targeting KRASG12C in colorectal cancer: the beginning of a new era. Ciardiello D, Maiorano BA, Martinelli E. ESMO Open 8 100745 (2023)
  66. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Sunaga N, Miura Y, Kasahara N, Sakurai R. Cancers (Basel) 13 5956 (2021)
  67. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Adachi Y, Kimura R, Hirade K, Ebi H. Cancers (Basel) 13 5081 (2021)
  68. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cekani E, Epistolio S, Dazio G, Cefalì M, Wannesson L, Frattini M, Froesch P. Cancers (Basel) 14 4103 (2022)
  69. RAS pathway regulation in melanoma. Al Mahi A, Ablain J. Dis Model Mech 15 dmm049229 (2022)
  70. Small molecule inhibitors of RAS proteins with oncogenic mutations. Orgován Z, Keserű GM. Cancer Metastasis Rev 39 1107-1126 (2020)
  71. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. Santarpia M, Ciappina G, Spagnolo CC, Squeri A, Passalacqua MI, Aguilar A, Gonzalez-Cao M, Giovannetti E, Silvestris N, Rosell R. Transl Lung Cancer Res 12 346-368 (2023)
  72. Targeting KRAS in PDAC: A New Way to Cure It? He Q, Liu Z, Wang J. Cancers (Basel) 14 4982 (2022)
  73. The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review. Ladak RJ, He AJ, Huang YH, Ding Y. Front Immunol 13 885371 (2022)
  74. The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function. Abdelkarim H, Banerjee A, Grudzien P, Leschinsky N, Abushaer M, Gaponenko V. Int J Mol Sci 20 E5718 (2019)
  75. Understand KRAS and the Quest for Anti-Cancer Drugs. Han CW, Jeong MS, Jang SB. Cells 10 842 (2021)
  76. Computer-Aided Drug Design Boosts RAS Inhibitor Discovery. Wang G, Bai Y, Cui J, Zong Z, Gao Y, Zheng Z. Molecules 27 5710 (2022)
  77. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. Köhler J, Jänne PA. Int J Mol Sci 22 3025 (2021)
  78. Pulmonary metastasectomy in colorectal carcinoma. Beckers P, Berzenji L, Yogeswaran SK, Lauwers P, Bilotta G, Shkarpa N, Hendriks J, Van Schil PE. J Thorac Dis 13 2628-2635 (2021)
  79. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers. Hyun S, Shin D. Int J Mol Sci 22 12142 (2021)
  80. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. Cancers (Basel) 14 5306 (2022)
  81. Cutting the Brakes on Ras-Cytoplasmic GAPs as Targets of Inactivation in Cancer. Bellazzo A, Collavin L. Cancers (Basel) 12 E3066 (2020)
  82. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. Garcia-Robledo JE, Rosell R, Ruíz-Patiño A, Sotelo C, Arrieta O, Zatarain-Barrón L, Ordoñez C, Jaller E, Rojas L, Russo A, de Miguel-Pérez D, Rolfo C, Cardona AF. Ther Adv Respir Dis 16 17534666211066064 (2022)
  83. Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives. Tisi R, Gaponenko V, Vanoni M, Sacco E. Biomolecules 10 E1535 (2020)
  84. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Front Oncol 12 931774 (2022)
  85. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Yang H, Zhou X, Fu D, Le C, Wang J, Zhou Q, Liu X, Yuan Y, Ding K, Xiao Q. Cancer Commun (Lond) 43 42-74 (2023)
  86. KRAS G12C inhibition and innate immune targeting. Tani T, Kitajima S, Conway EB, Knelson EH, Barbie DA. Expert Opin Ther Targets 25 167-174 (2021)
  87. RAS-targeted cancer therapy: Advances in drugging specific mutations. Liu C, Ye D, Yang H, Chen X, Su Z, Li X, Ding M, Liu Y. MedComm (2020) 4 e285 (2023)
  88. KRASG12R-Independent Macropinocytosis in Pancreatic Cancer. Hobbs GA, Der CJ. Subcell Biochem 98 205-221 (2022)
  89. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. Zhou X, Ji Y, Zhou J. Molecules 28 3615 (2023)
  90. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa. Jafari M, Laraqui A, Baba W, Benmokhtar S, Zaitouni SE, Ali AA, Bounaim A, Moujahid M, Tanz R, Mahfoud T, Sbitti Y, Annaz HE, Abi R, Tagajdid MR, Kochri SE, Lahlou IA, Hsaini HE, Belayachi L, Benjouad A, Ichou M, En-Nya A, Ennibi K. BMC Cancer 22 1142 (2022)
  91. Targeting protein conformations with small molecules to control protein complexes. Zacharioudakis E, Gavathiotis E. Trends Biochem Sci 47 1023-1037 (2022)
  92. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Tria SM, Burge ME, Whitehall VLJ. Cancers (Basel) 15 2375 (2023)
  93. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. J Mol Biol 434 167626 (2022)
  94. Comprehensive review of α-carboline alkaloids: Natural products, updated synthesis, and biological activities. Li D, Yang R, Wu J, Zhong B, Li Y. Front Chem 10 988327 (2022)
  95. PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy. Kelm JM, Pandey DS, Malin E, Kansou H, Arora S, Kumar R, Gavande NS. Mol Cancer 22 62 (2023)
  96. RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming. Miller-Phillips L, Collisson EA. Curr Treat Options Oncol 24 1088-1101 (2023)
  97. Small molecular inhibitors for KRAS-mutant cancers. Wu X, Song W, Cheng C, Liu Z, Li X, Cui Y, Gao Y, Li D. Front Immunol 14 1223433 (2023)
  98. Targeting the "undruggable" RAS with biologics. Whaby M, Khan I, O'Bryan JP. Adv Cancer Res 153 237-266 (2022)
  99. YB-1 activating cascades as potential targets in KRAS-mutated tumors. Khozooei S, Veerappan S, Toulany M. Strahlenther Onkol 199 1110-1127 (2023)
  100. Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg. Rosen JC, Sacher A, Tsao MS. Ther Adv Med Oncol 15 17588359231160141 (2023)
  101. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. Int J Biol Sci 19 3360-3382 (2023)
  102. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y, Liu QP, Xie H, Ding J. Acta Pharmacol Sin (2023)
  103. Heterogeneity in RAS mutations: One size does not fit all. Sealover NE, Kortum RL. Sci Signal 15 eadc9816 (2022)
  104. KRAS inhibition in metastatic colorectal cancer: An update. Nusrat M, Yaeger R. Curr Opin Pharmacol 68 102343 (2023)
  105. Protein conformational ensembles in function: roles and mechanisms. Nussinov R, Liu Y, Zhang W, Jang H. RSC Chem Biol 4 850-864 (2023)
  106. Shifting the Focus of Signaling Abnormalities in Colon Cancer. Brown MA, Ried T. Cancers (Basel) 14 784 (2022)
  107. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Wang P, Laster K, Jia X, Dong Z, Liu K. Mol Cancer 22 208 (2023)
  108. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. Bteich F, Mohammadi M, Li T, Bhat MA, Sofianidi A, Wei N, Kuang C. Int J Mol Sci 24 12030 (2023)
  109. Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure. de Jesus VHF, Mathias-Machado MC, de Farias JPF, Aruquipa MPS, Jácome AA, Peixoto RD. Cancers (Basel) 15 5015 (2023)
  110. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Caughey BA, Strickler JH. Drugs 84 27-44 (2024)
  111. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS. Yin G, Huang J, Petela J, Jiang H, Zhang Y, Gong S, Wu J, Liu B, Shi J, Gao Y. Signal Transduct Target Ther 8 212 (2023)
  112. The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application. Yu K, Wang Y. Pathol Oncol Res 27 1609906 (2021)
  113. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review. Derwich A, Sykutera M, Bromińska B, Rubiś B, Ruchała M, Sawicka-Gutaj N. Int J Mol Sci 24 10952 (2023)

Articles citing this publication (199)

  1. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. Cancer Discov 10 54-71 (2020)
  2. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Nature 577 421-425 (2020)
  3. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. Nat Cell Biol 20 1064-1073 (2018)
  4. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R. Nat Med 24 961-967 (2018)
  5. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, Werbeck ND, Briem H, Boemer U, Weiske J, Badock V, Mastouri J, Petersen K, Siemeister G, Kahmann JD, Wegener D, Böhnke N, Eis K, Graham K, Wortmann L, von Nussbaum F, Bader B. Proc Natl Acad Sci U S A 116 2551-2560 (2019)
  6. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. Cancer Discov 10 1129-1139 (2020)
  7. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, Araki K, Ozerdem U, Simeone DM, Miller G, Neel BG, Tang KH. Cancer Discov 8 1237-1249 (2018)
  8. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, Wunberg T, Zoephel A, Fu SC, Teh JL, Böttcher J, Pototschnig N, Schachinger F, Schipany K, Lieb S, Vellano CP, O'Connell JC, Mendes RL, Moll J, Petronczki M, Heffernan TP, Pearson M, McConnell DB, Kraut N. Cancer Discov 11 142-157 (2021)
  9. Drugging an undruggable pocket on KRAS. Kessler D, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, Gollner A, Covini D, Fischer S, Gerstberger T, Gmaschitz T, Goodwin C, Greb P, Häring D, Hela W, Hoffmann J, Karolyi-Oezguer J, Knesl P, Kornigg S, Koegl M, Kousek R, Lamarre L, Moser F, Munico-Martinez S, Peinsipp C, Phan J, Rinnenthal J, Sai J, Salamon C, Scherbantin Y, Schipany K, Schnitzer R, Schrenk A, Sharps B, Siszler G, Sun Q, Waterson A, Wolkerstorfer B, Zeeb M, Pearson M, Fesik SW, McConnell DB. Proc Natl Acad Sci U S A 116 15823-15829 (2019)
  10. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ. Nat Med 24 968-977 (2018)
  11. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M. Nat Med 25 1422-1427 (2019)
  12. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Fedele C, Li S, Teng KW, Foster CJR, Peng D, Ran H, Mita P, Geer MJ, Hattori T, Koide A, Wang Y, Tang KH, Leinwand J, Wang W, Diskin B, Deng J, Chen T, Chen T, Dolgalev I, Ozerdem U, Miller G, Koide S, Wong KK, Neel BG. J Exp Med 218 e20201414 (2021)
  13. Tissue-Specific Oncogenic Activity of KRASA146T. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Cancer Discov 9 738-755 (2019)
  14. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Cancer Discov 10 104-123 (2020)
  15. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, Poulikakos PI. Cell Rep 26 65-78.e5 (2019)
  16. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Escobar-Hoyos LF, Penson A, Kannan R, Cho H, Pan CH, Singh RK, Apken LH, Hobbs GA, Luo R, Lecomte N, Babu S, Pan FC, Alonso-Curbelo D, Morris JP, Askan G, Grbovic-Huezo O, Ogrodowski P, Bermeo J, Saglimbeni J, Cruz CD, Ho YJ, Lawrence SA, Melchor JP, Goda GA, Bai K, Pastore A, Hogg SJ, Raghavan S, Bailey P, Chang DK, Biankin A, Shroyer KR, Wolpin BM, Aguirre AJ, Ventura A, Taylor B, Der CJ, Dominguez D, Kümmel D, Oeckinghaus A, Lowe SW, Bradley RK, Abdel-Wahab O, Leach SD. Cancer Cell 38 198-211.e8 (2020)
  17. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Shin SM, Choi DK, Jung K, Bae J, Kim JS, Park SW, Song KH, Kim YS. Nat Commun 8 15090 (2017)
  18. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. Ntai I, Fornelli L, DeHart CJ, Hutton JE, Doubleday PF, LeDuc RD, van Nispen AJ, Fellers RT, Whiteley G, Boja ES, Rodriguez H, Kelleher NL. Proc Natl Acad Sci U S A 115 4140-4145 (2018)
  19. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M. Proc Natl Acad Sci U S A 116 22122-22131 (2019)
  20. Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Cruz-Migoni A, Canning P, Quevedo CE, Bataille CJR, Bery N, Miller A, Russell AJ, Phillips SEV, Carr SB, Rabbitts TH. Proc Natl Acad Sci U S A 116 2545-2550 (2019)
  21. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP. Nat Struct Mol Biol 25 454-462 (2018)
  22. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. Terrell EM, Durrant DE, Ritt DA, Sealover NE, Sheffels E, Spencer-Smith R, Esposito D, Zhou Y, Hancock JF, Kortum RL, Morrison DK. Mol Cell 76 872-884.e5 (2019)
  23. Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States. Gentile DR, Rathinaswamy MK, Jenkins ML, Moss SM, Siempelkamp BD, Renslo AR, Burke JE, Shokat KM. Cell Chem Biol 24 1455-1466.e14 (2017)
  24. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Winters IP, Chiou SH, Paulk NK, McFarland CD, Lalgudi PV, Ma RK, Lisowski L, Connolly AJ, Petrov DA, Kay MA, Winslow MM. Nat Commun 8 2053 (2017)
  25. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. Nat Commun 12 1808 (2021)
  26. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhang ZY, Tsao MS, Ikura M, Ohh M. Nat Commun 10 224 (2019)
  27. GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf. Zhang Z, Gao R, Hu Q, Peacock H, Peacock DM, Dai S, Shokat KM, Suga H. ACS Cent Sci 6 1753-1761 (2020)
  28. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Unni AM, Harbourne B, Oh MH, Wild S, Ferrarone JR, Lockwood WW, Varmus H. Elife 7 e33718 (2018)
  29. Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding. McCarthy MJ, Pagba CV, Prakash P, Naji AK, van der Hoeven D, Liang H, Gupta AK, Zhou Y, Cho KJ, Hancock JF, Gorfe AA. ACS Omega 4 2921-2930 (2019)
  30. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, Bertotti A, Sassi F, Sipieter F, Cappe B, Mertens S, Verlaan-Klink I, Boj SF, Vries RGJ, Rehmann H, Vandenabeele P, Riquet FB, Trusolino L, Bos JL, Snippert HJG. Nat Cell Biol 23 377-390 (2021)
  31. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions. Nakhaeizadeh H, Amin E, Nakhaei-Rad S, Dvorsky R, Ahmadian MR. PLoS One 11 e0167145 (2016)
  32. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D. Johnson CW, Lin YJ, Reid D, Parker J, Pavlopoulos S, Dischinger P, Graveel C, Aguirre AJ, Steensma M, Haigis KM, Mattos C. Cell Rep 28 1538-1550.e7 (2019)
  33. An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants. Zafra MP, Parsons MJ, Kim J, Alonso-Curbelo D, Goswami S, Schatoff EM, Han T, Katti A, Fernandez MTC, Wilkinson JE, Piskounova E, Dow LE. Cancer Discov 10 1654-1671 (2020)
  34. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ. Sci Signal 10 eaao3332 (2017)
  35. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Kim W, Lee S, Kim HS, Song M, Cha YH, Kim YH, Shin J, Lee ES, Joo Y, Song JJ, Choi EJ, Choi JW, Lee J, Kang M, Yook JI, Lee MG, Kim YS, Paik S, Kim HH. Genome Res (2018)
  36. Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling. Pantsar T, Rissanen S, Dauch D, Laitinen T, Vattulainen I, Poso A. PLoS Comput Biol 14 e1006458 (2018)
  37. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Liao S, Maertens O, Cichowski K, Elledge SJ. Genes Dev 32 1188-1200 (2018)
  38. Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, Ferrer I, Paz-Ares L, Gephart MH, Vicent S, Cochran JR, Sweet-Cordero EA. Nat Med 25 1783-1795 (2019)
  39. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. ACS Med Chem Lett 8 61-66 (2017)
  40. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. Bery N, Cruz-Migoni A, Bataille CJ, Quevedo CE, Tulmin H, Miller A, Russell A, Phillips SE, Carr SB, Rabbitts TH. Elife 7 e37122 (2018)
  41. Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States. Lim S, Khoo R, Juang YC, Gopal P, Zhang H, Yeo C, Peh KM, Teo J, Ng S, Henry B, Partridge AW. ACS Cent Sci 7 274-291 (2021)
  42. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y, Du Y, Chen CC, Guo RT, Zhang Y. Cell Discov 8 5 (2022)
  43. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Mol Cancer Ther 20 2577-2584 (2021)
  44. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Vasta JD, Peacock DM, Zheng Q, Walker JA, Zhang Z, Zimprich CA, Thomas MR, Beck MT, Binkowski BF, Corona CR, Robers MB, Shokat KM. Nat Chem Biol 18 596-604 (2022)
  45. Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile. Zhang Z, Morstein J, Ecker AK, Guiley KZ, Shokat KM. J Am Chem Soc 144 15916-15921 (2022)
  46. Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants. Sayyed-Ahmad A, Prakash P, Gorfe AA. Proteins 85 1618-1632 (2017)
  47. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Zhang Z, Guiley KZ, Shokat KM. Nat Chem Biol 18 1177-1183 (2022)
  48. Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras. Xu S, Long BN, Boris GH, Chen A, Ni S, Kennedy MA. Acta Crystallogr D Struct Biol 73 970-984 (2017)
  49. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Lu J, Bera AK, Gondi S, Westover KD. Biochemistry 57 324-333 (2018)
  50. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Song HY, Biancucci M, Kang HJ, O'Callaghan C, Park SH, Principe DR, Jiang H, Yan Y, Satchell KF, Raparia K, Gius D, Vassilopoulos A. Oncotarget 7 80336-80349 (2016)
  51. Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal syndrome and encephalocraniocutaneous lipomatosis. Boppudi S, Bögershausen N, Hove HB, Percin EF, Aslan D, Dvorsky R, Kayhan G, Li Y, Cursiefen C, Tantcheva-Poor I, Toft PB, Bartsch O, Lissewski C, Wieland I, Jakubiczka S, Wollnik B, Ahmadian MR, Heindl LM, Zenker M. Clin Genet 90 334-342 (2016)
  52. Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR. J Mol Biol 428 4723-4735 (2016)
  53. Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras. Vatansever S, Erman B, Gümüş ZH. Comput Struct Biotechnol J 18 1000-1011 (2020)
  54. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Li C, Vides A, Kim D, Xue JY, Zhao Y, Lito P. Science 374 197-201 (2021)
  55. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel. Killoran RC, Smith MJ. J Biol Chem 294 9937-9948 (2019)
  56. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, Chen X, Cui X, de Kanter R, Dharmarajan L, Fedele C, Gerspacher M, Guthy DA, Head V, Jaeger A, Núñez EJ, Kearns JD, Leblanc C, Maira SM, Murphy J, Oakman H, Ostermann N, Ottl J, Rigollier P, Roman D, Schnell C, Sedrani R, Shimizu T, Stringer R, Vaupel A, Voshol H, Wessels P, Widmer T, Wilcken R, Xu K, Zecri F, Farago AF, Cotesta S, Brachmann SM. Cancer Discov 12 1500-1517 (2022)
  57. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Sheffels E, Sealover NE, Wang C, Kim DH, Vazirani IA, Lee E, M Terrell E, Morrison DK, Luo J, Kortum RL. Sci Signal 11 eaar8371 (2018)
  58. Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Ottaiano A, Normanno N, Facchini S, Cassata A, Nappi A, Romano C, Silvestro L, De Stefano A, Rachiglio AM, Roma C, Maiello MR, Scala S, Delrio P, Tatangelo F, Di Mauro A, Botti G, Avallone A, Nasti G. Cancers (Basel) 12 E1919 (2020)
  59. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, Yoshino T. Oncologist 26 845-853 (2021)
  60. Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway. Gillies TE, Pargett M, Silva JM, Teragawa CK, McCormick F, Albeck JG. Mol Syst Biol 16 e9518 (2020)
  61. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. Johnson C, Burkhart DL, Haigis KM. Cancer Discov 12 913-923 (2022)
  62. Structural basis of the atypical activation mechanism of KRASV14I. Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. J Biol Chem 294 13964-13972 (2019)
  63. Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing. Wang Y, Yu M, Yang JX, Cao DY, Zhang Y, Zhou HM, Yuan Z, Shen K. Front Oncol 9 123 (2019)
  64. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. Levin N, Paria BC, Vale NR, Yossef R, Lowery FJ, Parkhurst MR, Yu Z, Florentin M, Cafri G, Gartner JJ, Shindorf ML, Ngo LT, Ray S, Kim SP, Copeland AR, Robbins PF, Rosenberg SA. Clin Cancer Res 27 5084-5095 (2021)
  65. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. Structure 25 1442-1448.e3 (2017)
  66. Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, Liu L, Cheng X, Zeng W. Int J Clin Exp Pathol 12 957-967 (2019)
  67. 1H, 15N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH. Pálfy G, Vida I, Perczel A. Biomol NMR Assign 14 1-7 (2020)
  68. A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation. Simanshu DK, Morrison DK. Cancer Discov 12 899-912 (2022)
  69. Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR. Toyama Y, Kontani K, Katada T, Shimada I. Sci Adv 5 eaav8945 (2019)
  70. Insights into cancer severity from biomolecular interaction mechanisms. Raimondi F, Singh G, Betts MJ, Apic G, Vukotic R, Andreone P, Stein L, Russell RB, Russell RB. Sci Rep 6 34490 (2016)
  71. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Gebregiworgis T, Kano Y, St-Germain J, Radulovich N, Udaskin ML, Mentes A, Huang R, Poon BPK, He W, Valencia-Sama I, Robinson CM, Huestis M, Miao J, Yeh JJ, Zhang ZY, Irwin MS, Lee JE, Tsao MS, Raught B, Marshall CB, Ohh M, Ikura M. Nat Commun 12 6274 (2021)
  72. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. Nature 619 160-166 (2023)
  73. Q61 mutant-mediated dynamics changes of the GTP-KRAS complex probed by Gaussian accelerated molecular dynamics and free energy landscapes. Chen J, Zeng Q, Wang W, Hu Q, Bao H. RSC Adv 12 1742-1757 (2022)
  74. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. Stites EC, Shaw AS. CPT Pharmacometrics Syst Pharmacol 7 342-351 (2018)
  75. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Nature 603 335-342 (2022)
  76. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. MedComm (2020) 1 121-128 (2020)
  77. KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition. Janardhan HP, Meng X, Dresser K, Hutchinson L, Trivedi CM. J Exp Med 217 e20192205 (2020)
  78. Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine-dependent interface: a model for KRAS oligomerization. Lee KY, Enomoto M, Gebregiworgis T, Gasmi-Seabrook GMC, Ikura M, Marshall CB. Chem Sci 12 12827-12837 (2021)
  79. Structural impact of GTP binding on downstream KRAS signaling. Menyhárd DK, Pálfy G, Orgován Z, Vida I, Keserű GM, Perczel A. Chem Sci 11 9272-9289 (2020)
  80. Active and Inactive Cdc42 Differ in Their Insert Region Conformational Dynamics. Haspel N, Jang H, Nussinov R. Biophys J 120 306-318 (2021)
  81. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P, Montesion M, Schutzman JL, Ye X, Hegde PS, Nagasaka M, Oxnard GR, Sokol ES, Ou SI, Shi Z. NPJ Precis Oncol 6 91 (2022)
  82. Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor. Buyanova M, Cai S, Cooper J, Rhodes C, Salim H, Sahni A, Upadhyaya P, Yang R, Sarkar A, Li N, Wang QE, Pei D. J Med Chem 64 13038-13053 (2021)
  83. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants. Moghadamchargari Z, Shirzadeh M, Liu C, Schrecke S, Packianathan C, Russell DH, Zhao M, Laganowsky A. Proc Natl Acad Sci U S A 118 e2022403118 (2021)
  84. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma. Nastasă C, Tamaian R, Oniga O, Tiperciuc B. Medicina (Kaunas) 55 E85 (2019)
  85. Free Energy Profiles Relating With Conformational Transition of the Switch Domains Induced by G12 Mutations in GTP-Bound KRAS. Chen J, Zhang S, Zeng Q, Wang W, Zhang Q, Liu X. Front Mol Biosci 9 912518 (2022)
  86. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S. Cell Death Dis 11 930 (2020)
  87. A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency. Lagresle-Peyrou C, Olichon A, Sadek H, Roche P, Tardy C, Da Silva C, Garrigue A, Fischer A, Moshous D, Collette Y, Picard C, Casanova JL, André I, Cavazzana M. Haematologica 106 404-411 (2021)
  88. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. McFall T, Stites EC. Mol Cell Oncol 7 1701914 (2020)
  89. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. McFall T, Schomburg NK, Rossman KL, Stites EC. Cell Commun Signal 18 179 (2020)
  90. Functional and biological heterogeneity of KRASQ61 mutations. Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, DeLiberty JM, Thurman RD, Cooke AR, Goodwin CM, Cook JH, Lin L, Waters AM, Rashid NU, Petricoin EF, Campbell SL, Haigis KM, Simeone DM, Lyssiotis CA, Cox AD, Der CJ. Sci Signal 15 eabn2694 (2022)
  91. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Cell Rep 38 110322 (2022)
  92. Structural basis for SHOC2 modulation of RAS signalling. Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J. Nature 609 400-407 (2022)
  93. The Importance of Mg2+ -Free State in Nucleotide Exchange of Oncogenic K-Ras Mutants. Pálfy G, Menyhárd DK, Ákontz-Kiss H, Vida I, Batta G, Tőke O, Perczel A. Chemistry 28 e202201449 (2022)
  94. The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. Wahl SGF, Dai HY, Emdal EF, Berg T, Halvorsen TO, Ottestad AL, Lund-Iversen M, Brustugun OT, Førde D, Paulsen EE, Donnem T, Andersen S, Grønberg BH, Richardsen E. Cancers (Basel) 13 4294 (2021)
  95. Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. Park HE, Yoo SY, Cho NY, Bae JM, Han SW, Lee HS, Park KJ, Kim TY, Kang GH. Sci Rep 11 14609 (2021)
  96. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cheng R, Li F, Zhang M, Xia X, Wu J, Gao X, Zhou H, Zhang Z, Huang N, Yang X, Zhang Y, Shen S, Kang T, Liu Z, Xiao F, Yao H, Xu J, Yan C, Zhang N. Cell Res 33 30-45 (2023)
  97. A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors. Feng S, Callow MG, Fortin JP, Khan Z, Bray D, Costa M, Shi Z, Wang W, Evangelista M. Proc Natl Acad Sci U S A 119 e2120512119 (2022)
  98. A saturation-mutagenesis analysis of the interplay between stability and activation in Ras. Hidalgo F, Nocka LM, Shah NH, Gorday K, Latorraca NR, Bandaru P, Templeton S, Lee D, Karandur D, Pelton JG, Marqusee S, Wemmer D, Kuriyan J. Elife 11 e76595 (2022)
  99. Assessing optimal: inequalities in codon optimization algorithms. Ranaghan MJ, Li JJ, Laprise DM, Garvie CW. BMC Biol 19 36 (2021)
  100. Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1). Fang Z, Marshall CB, Yin JC, Mazhab-Jafari MT, Gasmi-Seabrook GM, Smith MJ, Nishikawa T, Xu Y, Neel BG, Ikura M. J Biol Chem 291 15641-15652 (2016)
  101. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Issahaku AR, Mukelabai N, Agoni C, Rudrapal M, Aldosari SM, Almalki SG, Khan J. Sci Rep 12 17796 (2022)
  102. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. JCO Precis Oncol 5 PO.21.00223 (2021)
  103. Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Liu Y, Gao GF, Minna JD, Williams NS, Westover KD. Lung Cancer 153 73-80 (2021)
  104. Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer. Liu H, Liang Z, Cheng S, Huang L, Li W, Zhou C, Zheng X, Li S, Zeng Z, Kang L. Adv Sci (Weinh) 10 e2203757 (2023)
  105. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Hung PS, Huang MH, Kuo YY, Yang JC. Cancers (Basel) 12 E837 (2020)
  106. A New View of Activating Mutations in Cancer. Nussinov R, Tsai CJ, Jang H. Cancer Res 82 4114-4123 (2022)
  107. Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C. Li C, Zhao N, An L, Dai Z, Chen X, Yang F, You Q, Di B, Hu C, Xu L. Acta Pharm Sin B 11 2670-2684 (2021)
  108. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer. Ohnami S, Maruyama K, Chen K, Takahashi Y, Hatakeyama K, Ohshima K, Shimoda Y, Sakai A, Kamada F, Nakatani S, Naruoka A, Ohnami S, Kusuhara M, Akiyama Y, Kagawa H, Shiomi A, Nagashima T, Urakami K, Yamaguchi K. Mol Cell Biochem 476 3469-3482 (2021)
  109. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M. Br J Cancer 126 744-753 (2022)
  110. Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling. Marín-Ramos NI, Piñar C, Vázquez-Villa H, Martín-Fontecha M, González Á, Canales Á, Algar S, Mayo PP, Jiménez-Barbero J, Gajate C, Mollinedo F, Pardo L, Ortega-Gutiérrez S, Viso A, López-Rodríguez ML. Chemistry 23 1676-1685 (2017)
  111. Dynamic regulation of RAS and RAS signaling. Kolch W, Berta D, Rosta E. Biochem J 480 1-23 (2023)
  112. Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target. Adeniji EA, Olotu FA, Soliman MES. Anticancer Agents Med Chem 18 1540-1550 (2018)
  113. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, Vázquez-García I, Weigelt B, Wu M, Zamarin D, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, Łuksza M, Greenbaum BD. Nature 606 172-179 (2022)
  114. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Wallon L, Khan I, Teng KW, Koide A, Zuberi M, Li J, Ketavarapu G, Traaseth NJ, O'Bryan JP, Koide S. Proc Natl Acad Sci U S A 119 e2204481119 (2022)
  115. Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K. Angeles AKJ, Yu RTD, Cutiongco-De La Paz EM, Garcia RL. Oncol Lett 18 420-432 (2019)
  116. SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma. Zhou P, Xiao M, Li W, Sun X, Bai Y, Meng F, Zhu Z, Yuan W, Sun K. Front Pharmacol 13 841308 (2022)
  117. Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations. Tripathi S, Dsouza NR, Urrutia R, Zimmermann MT. Bioinformatics 37 1367-1375 (2021)
  118. Structural dataset for the fast-exchanging KRAS G13D. Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD. Data Brief 5 572-578 (2015)
  119. Structure of an inactive conformation of GTP-bound RhoA GTPase. Lin Y, Lu S, Zhang J, Zheng Y. Structure 29 553-563.e5 (2021)
  120. Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability. Kopra K, Valtonen S, Mahran R, Kapp JN, Hassan N, Gillette W, Dennis B, Li L, Westover KD, Plückthun A, Härmä H. Int J Mol Sci 23 7095 (2022)
  121. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. Jiang Z, Cheng L, Wu Z, Zhou L, Wang H, Hong Q, Wu Q, Long Y, Huang Y, Xu G, Yao Y, Tang Z, Zhang Z, Yang L, Luo W, Yang J, Gong L, Liu P, Chen X, Cui S, Zhang Q, Li Y, Li P. EMBO Rep 23 e54275 (2022)
  122. A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Ely ZA, Mathey-Andrews N, Naranjo S, Gould SI, Mercer KL, Newby GA, Cabana CM, Rideout WM, Jaramillo GC, Khirallah JM, Holland K, Randolph PB, Freed-Pastor WA, Davis JR, Kulstad Z, Westcott PMK, Lin L, Anzalone AV, Horton BL, Pattada NB, Shanahan SL, Ye Z, Spranger S, Xu Q, Sánchez-Rivera FJ, Liu DR, Jacks T. Nat Biotechnol (2023)
  123. An Application of pET SUMO Protein Expression System in Escherichia coli: Cloning, Expression, Purification, and Characterisation of Native Kras4BG12V Oncoprotein. Tan MS, Teh YH, Ho KL, Stanslas J. Protein J 39 54-61 (2020)
  124. Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors. Davies CW, Oh AJ, Mroue R, Steffek M, Bruning JM, Xiao Y, Feng S, Jayakar S, Chan E, Arumugam V, Uribe SC, Drummond J, Frommlet A, Lu C, Franke Y, Merchant M, Koeppen H, Quinn JG, Malhotra S, Do S, Gazzard L, Purkey HE, Rudolph J, Mulvihill MM, Koerber JT, Wang W, Evangelista M. Nat Biotechnol 40 769-778 (2022)
  125. DNA Polymerase Theta Plays a Critical Role in Pancreatic Cancer Development and Metastasis. Smolinska A, Singer K, Golchert J, Smyczynska U, Fendler W, Sendler M, van den Brandt J, Singer S, Homuth G, Lerch MM, Moskwa P. Cancers (Basel) 14 4077 (2022)
  126. Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction. Durrant DE, Smith EA, Goncharova EI, Sharma N, Alexander PA, Stephen AG, Henrich CJ, Morrison DK. Mol Cancer Ther 20 1743-1754 (2021)
  127. Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics. Tripathi S, Dsouza NR, Mathison AJ, Leverence E, Urrutia R, Zimmermann MT. Comput Struct Biotechnol J 20 117-127 (2022)
  128. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. Birth Defects Res 112 708-717 (2020)
  129. Germline control of somatic Kras mutations in mouse lung tumors. Borrego A, Cabrera WHK, Jensen JR, Correa M, Ribeiro OG, Starobinas N, De Franco M, Pettinicchio A, Dragani TA, Ibañez OCM, Manenti G. Mol Carcinog 57 745-751 (2018)
  130. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep 37 110096 (2021)
  131. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Ma Y, Schulz B, Trakooljul N, Al Ammar M, Sekora A, Sender S, Hadlich F, Zechner D, Weiss FU, Lerch MM, Jaster R, Junghanss C, Murua Escobar H. Cancers (Basel) 14 4467 (2022)
  132. Integration of Heterogeneous Biological Data in Multiscale Mechanistic Model Calibration: Application to Lung Adenocarcinoma. Palgen JL, Perrillat-Mercerot A, Ceres N, Peyronnet E, Coudron M, Tixier E, Illigens BMW, Bosley J, L'Hostis A, Monteiro C. Acta Biotheor 70 19 (2022)
  133. KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement. Pagba CV, Gupta AK, Naji AK, van der Hoeven D, Churion K, Liang X, Jakubec J, Hook M, Zuo Y, Martinez de Kraatz M, Frost JA, Gorfe AA. ACS Bio Med Chem Au 2 617-626 (2022)
  134. Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Dong XD, Zhang M, Cai CY, Teng QX, Wang JQ, Fu YG, Cui Q, Patel K, Wang DT, Chen ZS. Front Pharmacol 13 843829 (2022)
  135. PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. Mansour MSI, Malmros K, Mager U, Ericson Lindquist K, Hejny K, Holmgren B, Seidal T, Dejmek A, Dobra K, Planck M, Brunnström H. Int J Mol Sci 23 4517 (2022)
  136. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines. Stubbs CK, Biancucci M, Vidimar V, Satchell KJF. Sci Rep 11 17925 (2021)
  137. The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells. Tisi R, Spinelli M, Palmioli A, Airoldi C, Cazzaniga P, Besozzi D, Nobile MS, Mazzoleni E, Arnhold S, De Gioia L, Grandori R, Peri F, Vanoni M, Sacco E. Front Mol Biosci 8 625979 (2021)
  138. A germline mutation in Rab43 gene identified from a cancer family predisposes to a hereditary liver-colon cancer syndrome. Jiang Y, Sun Y, Hu J, Yu N, Liu H, Fan J, Ning X, Li Y, Liu B, Sun Y, Zhang J, Qiu X, Fu S, Zhou C, Xu H. BMC Cancer 19 613 (2019)
  139. Catalytically Competent Non-transforming H-RASG12P Mutant Provides Insight into Molecular Switch Function and GAP-independent GTPase Activity of RAS. Ilter M, Sensoy O. Sci Rep 9 10967 (2019)
  140. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Cancers (Basel) 14 4933 (2022)
  141. Delineating the RAS Conformational Landscape. Parker MI, Meyer JE, Golemis EA, Dunbrack RL. Cancer Res 82 2485-2498 (2022)
  142. HPLC method to resolve, identify and quantify guanine nucleotides bound to recombinant ras GTPase. Hannan JP, Swisher GH, Martyr JG, Cordaro NJ, Erbse AH, Falke JJ. Anal Biochem 631 114338 (2021)
  143. News Harnessing Antibody-Mimetic Selectivity for Activation-State-Specific Targeted Degradation of Endogenous K-Ras. Ferguson FM. ACS Cent Sci 7 222-224 (2021)
  144. Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. Álvarez-Prado ÁF, Maas RR, Soukup K, Klemm F, Kornete M, Krebs FS, Zoete V, Berezowska S, Brouland JP, Hottinger AF, Daniel RT, Hegi ME, Joyce JA. Cell Rep Med 4 100900 (2023)
  145. KRAS inhibitors: going noncovalent. Drosten M, Barbacid M. Mol Oncol 16 3911-3915 (2022)
  146. Millisecond molecular dynamics simulations of KRas-dimer formation and interfaces. Ngo VA, Garcia AE. Biophys J 121 3730-3744 (2022)
  147. Novel, provable algorithms for efficient ensemble-based computational protein design and their application to the redesign of the c-Raf-RBD:KRas protein-protein interface. Lowegard AU, Frenkel MS, Holt GT, Jou JD, Ojewole AA, Donald BR. PLoS Comput Biol 16 e1007447 (2020)
  148. Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K-Ras4b Inhibitors. Jeuken S, Shkura O, Röger M, Brickau V, Choidas A, Degenhart C, Gülden D, Klebl B, Koch U, Stoll R, Scherkenbeck J. ChemMedChem 17 e202200392 (2022)
  149. Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors. Tawfeeq N, Jin Y, Lamango NS. Cancers (Basel) 13 5757 (2021)
  150. Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation. Li Y, Han L, Zhang Z. Comput Struct Biotechnol J 20 1056-1067 (2022)
  151. Catalytic site mutations confer multiple states of G protein activation. Hewitt N, Ma N, Arang N, Martin SA, Prakash A, DiBerto JF, Knight KM, Ghosh S, Olsen RHJ, Roth BL, Gutkind JS, Vaidehi N, Campbell SL, Dohlman HG. Sci Signal 16 eabq7842 (2023)
  152. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. McFall T, Trogdon M, Guizar AC, Langenheim JF, Sisk-Hackworth L, Stites EC. NPJ Precis Oncol 6 86 (2022)
  153. Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors. Liu M, Zhou G, Su W, Gu Y, Gao M, Wang K, Huo R, Li Y, Zhou Z, Chen K, Zheng M, Zhang S, Xu T. ACS Med Chem Lett 14 183-190 (2023)
  154. Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer. Wang L, Lin S, Yang C, Cai S, Li W. Mol Genet Genomic Med 10 e1905 (2022)
  155. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein. Janssen K, Claes F, Van de Velde D, Wehbi VL, Houben B, Lampi Y, Nys M, Khodaparast L, Khodaparast L, Louros N, van der Kant R, Verniers J, Garcia T, Ramakers M, Konstantoulea K, Maragkou K, Duran-Romaña R, Musteanu M, Barbacid M, Scorneaux B, Beirnaert E, Schymkowitz J, Rousseau F. Proc Natl Acad Sci U S A 120 e2214921120 (2023)
  156. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, Lenoue-Newton ML, Rizvi HA, White JR, Baras AS, Anaya J, Landon BV, Majcherska-Agrawal M, Ghanem P, Lee J, Raskin L, Park AS, Tu H, Hsu H, Arbour KC, Awad MM, Riely GJ, Lovly CM, Anagnostou V. Cancer Res 82 4058-4078 (2022)
  157. Case Reports Identification of Codon 146 KRAS Variants in Isolated Epidermal Nevus and Multiple Lesions in Oculoectodermal Syndrome: Confirmation of the Phenotypic Continuum of Mosaic RASopathies. Beyens A, Dequeker L, Brems H, Janssens S, Syryn H, D'Hooghe A, De Paepe P, Vanwalleghem L, Stockman A, Vankwikelberge E, De Schepper S, Goeteyn M, Delbeke P, Callewaert B. Int J Mol Sci 23 4036 (2022)
  158. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Stites EC. Methods Mol Biol 2262 311-321 (2021)
  159. Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors. Dias Carvalho P, Martins F, Carvalho J, Oliveira MJ, Velho S. Cells 11 1988 (2022)
  160. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. Ramzy GM, Norkin M, Koessler T, Voirol L, Tihy M, Hany D, McKee T, Ris F, Buchs N, Docquier M, Toso C, Rubbia-Brandt L, Bakalli G, Guerrier S, Huelsken J, Nowak-Sliwinska P. J Exp Clin Cancer Res 42 79 (2023)
  161. Studies on Biological and Molecular Effects of Small-Molecule Kinase Inhibitors on Human Glioblastoma Cells and Organotypic Brain Slices. Hörnschemeyer J, Kirschstein T, Reichart G, Sasse C, Venus J, Einsle A, Porath K, Linnebacher M, Köhling R, Lange F. Life (Basel) 12 1258 (2022)
  162. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background. Budagyan K, Chernoff J. Methods Mol Biol 2262 323-334 (2021)
  163. A single inhibitor for all KRAS mutations. Corcoran RB. Nat Cancer 4 1060-1062 (2023)
  164. AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Chakraborty A, Hanson L, Robinson D, Lewis H, Bickerton S, Davies M, Polanski R, Whiteley R, Koers A, Atkinson J, Baker T, Del Barco Barrantes I, Ciotta G, Kettle JG, Magiera L, Martins CP, Peter A, Wigmore E, Underwood Z, Cosulich S, Niedbala M, Ross S. Mol Cancer Ther 21 1535-1546 (2022)
  165. Actionability classification of variants of unknown significance correlates with functional effect. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Wang Y, Zeng J, Holla V, Vu T, Su F, Kim SH, Conway T, Jiang X, Chen K, Shaw KRM, Yap TA, Rodon J, Mills GB, Meric-Bernstam F. NPJ Precis Oncol 7 67 (2023)
  166. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity. Yang MH, Tran TH, Hunt B, Agnor R, Johnson CW, Shui B, Waybright TJ, Nowak JA, Stephen AG, Simanshu DK, Haigis KM. Cancer Res 83 3176-3183 (2023)
  167. Applying deep learning to segmentation of murine lung tumors in pre-clinical micro-computed tomography. Montgomery MK, Duan C, Manzuk L, Chang S, Cubias A, Brun S, Giddabasappa A, Jiang ZK. Transl Oncol 40 101833 (2024)
  168. Binding of active Ras and its mutants to the Ras binding domain of PI-3-kinase: A quantitative approach to KD measurements. Fleming IR, Hannan JP, Swisher GH, Tesdahl CD, Martyr JG, Cordaro NJ, Erbse AH, Falke JJ. Anal Biochem 663 115019 (2023)
  169. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer. Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M, Kottarathil T, Piquet M, Cao Y, Martinuzzi-Duboc L, Buhles A, Adler F, Mannino S, Tordella L, Sansregret L, Maira SM, Graus Porta D, Fedele C, Brachmann SM. Cancer Res 83 4130-4141 (2023)
  170. Computational Random Mutagenesis to Investigate RAS Mutant Signaling. Stites EC. Methods Mol Biol 2634 329-335 (2023)
  171. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma. Baltanás FC, García-Navas R, Rodríguez-Ramos P, Calzada N, Cuesta C, Borrajo J, Fuentes-Mateos R, Olarte-San Juan A, Vidaña N, Castellano E, Santos E. Nat Commun 14 5856 (2023)
  172. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist? Contreras-Toledo D, Jiménez-Fonseca P, López CL, Montes AF, López Muñoz AM, Vázquez Rivera F, Alonso V, Alcaide J, Salvà F, Covela Rúa M, Guillot M, Martín Carnicero A, Jimeno Mate R, Cameselle García S, Asensio Martínez E, González Astorga B, Fernandez-Diaz AB, González Villaroel P, Virgili Manrique AC, Melián Sosa M, Alonso B, Cousillas Castiñeiras A, Castañón López C, Aparicio J, Carmona-Bayonas A. Br J Cancer (2024)
  173. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer. Lee C, Jiang ZK, Planken S, Manzuk LK, Ortiz R, Hall M, Noorbehesht K, Ram S, Affolter T, Troche GE, Ihle NT, Johnson T, Ahn Y, Kraus M, Giddabasappa A. Mol Cancer Ther 22 891-900 (2023)
  174. Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models. Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE. Front Oncol 13 1094123 (2023)
  175. Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy. Veccia A, Dipasquale M, Kinspergher S, Monteverdi S, Girlando S, Barbareschi M, Caffo O. Target Oncol 18 129-138 (2023)
  176. Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations. Shi S, Zheng L, Ren Y, Wang Z. Molecules 28 2886 (2023)
  177. KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. Fancelli S, Caliman E, Mazzoni F, Paglialunga L, Gatta Michelet MR, Lavacchi D, Berardi R, Mentrasti G, Metro G, Birocchi I, Delmonte A, Priano I, Comin CE, Castiglione F, Bartoli C, Voltolini L, Pillozzi S, Antonuzzo L. Front Oncol 12 968064 (2022)
  178. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo. Najumudeen AK, Fey SK, Millett LM, Ford CA, Gilroy K, Gunduz N, Ridgway RA, Anderson E, Strathdee D, Clark W, Nixon C, Morton JP, Campbell AD, Sansom OJ. Nat Commun 15 100 (2024)
  179. KRAS mutations and endometriosis burden of disease. Orr NL, Albert A, Liu YD, Lum A, Hong J, Ionescu CL, Senz J, Nazeran TM, Lee AF, Noga H, Lawrenson K, Allaire C, Williams C, Bedaiwy MA, Anglesio MS, Yong PJ. J Pathol Clin Res 9 302-312 (2023)
  180. KRAS: Druggable at Last. Herzberg BO, Manji GA. Oncologist 28 283-286 (2023)
  181. Leveraging a KRAS-based signature to predict the prognosis and drug sensitivity of colon cancer and identifying SPINK4 as a new biomarker. Huo JT, Tuersun A, Yu SY, Zhang YC, Feng WQ, Xu ZQ, Zhao JK, Zong YP, Lu AG. Sci Rep 13 22230 (2023)
  182. Lysines K117 and K147 play conserved roles in Ras activation from Drosophila to mammals. Singh J, Karunaraj P, Luf M, Pfleger CM. G3 (Bethesda) 13 jkad201 (2023)
  183. Mechanism-Based Redesign of GAP to Activate Oncogenic Ras. Berta D, Gehrke S, Nyíri K, Vértessy BG, Rosta E. J Am Chem Soc 145 20302-20310 (2023)
  184. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer. Gökmen İ, Taştekin E, Demir N, Özcan E, Akgül F, Hacıoğlu MB, Erdoğan B, Topaloğlu S, Çiçin İ. Curr Issues Mol Biol 45 7803-7812 (2023)
  185. Multiplexed imaging for probing RAS-RAF interactions in living cells. Ahmad M, Movileanu L. Biochim Biophys Acta Biomembr 1865 184173 (2023)
  186. NMR 1H, 13C, 15N backbone resonance assignments of the T35S and oncogenic T35S/Q61L mutants of human KRAS4b in the active, GppNHp-bound conformation. Sharma AK, Dyba M, Tonelli M, Smith B, Gillette WK, Esposito D, Nissley DV, McCormick F, Maciag AE. Biomol NMR Assign 16 1-8 (2022)
  187. New pyrimidine-N-β-D-glucosides: synthesis, biological evaluation, and molecular docking investigations. Kahriman N, Peker K, Serdaroğlu V, Aydin A, Türkmenoğlu B, Usta A, Yayli N. Turk J Chem 47 476-494 (2023)
  188. Oncogenic context shapes the fitness landscape of tumor suppression. Blair LM, Juan JM, Sebastian L, Tran VB, Nie W, Wall GD, Gerceker M, Lai IK, Apilado EA, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, Chenchik A, Paz Zafra M, Dow LE, Politi K, MacQuitty JJ, Petrov DA, Winslow MM, Rosen MJ, Winters IP. Nat Commun 14 6422 (2023)
  189. Path Sampling Simulations Reveal How the Q61L Mutation Alters the Dynamics of KRas. Roet S, Hooft F, Bolhuis PG, Swenson DWH, Vreede J. J Phys Chem B 126 10034-10044 (2022)
  190. Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib. Nolan A, Raso C, Kolch W, Kriegsheim AV, Wynne K, Matallanas D. Cancers (Basel) 15 4141 (2023)
  191. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy. Zhao Q, Haga R, Tamura S, Shimada I, Nishida N. Sci Rep 13 19253 (2023)
  192. Reduced dynamic complexity allows structure elucidation of an excited state of KRASG13D. Chao FA, Chan AH, Dharmaiah S, Schwieters CD, Tran TH, Taylor T, Ramakrishnan N, Esposito D, Nissley DV, McCormick F, Simanshu DK, Cornilescu G. Commun Biol 6 594 (2023)
  193. Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma. Alon M, Emmanuel R, Qutob N, Bakhman A, Peshti V, Brodezki A, Bassan D, Kosloff M, Samuels Y. Pigment Cell Melanoma Res 31 641-648 (2018)
  194. S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist. Zhu D, Jiang T, Ma D, Zhang H, Zhang J, Lv W, Gong M, Wang H, Liu Z, Su H, Zeng L, Liu S, Tang S, Yang B, Tshavuka FI, Fu G, Liu Z, Peng D, Liu H, Yan Z, Cao Z, Zhao H, He TC, Yu J, Shu Y, Zou L. Leukemia 37 1982-1993 (2023)
  195. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Daley BR, Vieira HM, Rao C, Hughes JM, Beckley ZM, Huisman DH, Chatterjee D, Sealover NE, Cox K, Askew JW, Svoboda RA, Fisher KW, Lewis RE, Kortum RL. Proc Natl Acad Sci U S A 120 e2313137120 (2023)
  196. Small-Molecule Inhibition of KRAS through Conformational Selection. Pagba CV, Gupta AK, Gorfe AA. ACS Omega 8 31419-31426 (2023)
  197. Structural insights into the complex of oncogenic KRas4BG12V and Rgl2, a RalA/B activator. Tariq M, Ikeya T, Togashi N, Fairall L, Kamei S, Mayooramurugan S, Abbott LR, Hasan A, Bueno-Alejo C, Sukegawa S, Romartinez-Alonso B, Muro Campillo MA, Hudson AJ, Ito Y, Schwabe JW, Dominguez C, Tanaka K. Life Sci Alliance 7 e202302080 (2024)
  198. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. Goebel L, Kirschner T, Koska S, Rai A, Janning P, Maffini S, Vatheuer H, Czodrowski P, Goody RS, Müller MP, Rauh D. Elife 12 e82184 (2023)
  199. The Contributions of Trace Elements on Molecular Subtype-Specific Colorectal Cancer. Bai DX, Xiao JA, Huang TC, Shen ZL, Li L, Ding FF, Wen M, Wu SX, Liu XC, Jiang HH. J Cancer 14 1486-1498 (2023)


Quick links